Idenix Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Idenix Pharmaceuticals, Inc.
The deal leaves PRX004 in the capable hands of Novo Nordisk, which is hoping to expand beyond obesity and diabetes, while Prothena can focus on the rest of its pipeline.
Just under a year since Santhera restructured after disappointing late-stage clinical results with another DMD candidate, the Switzerland-headquartered company has reported positive top-line results in the condition with licensed-in vamorolone, and is planning for commercialization in late 2022/early 2023.
Market Snapshot: Acute myeloid leukemia is a serious condition that affects people mainly in late middle age, for which there is a large R&D pipeline of candidate products being researched by pharmaceutical and biotech companies, many of whom are using a targeted medicine approach.
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
- Other Names / Subsidiaries
- Novirio Pharmaceuticals Limited